Olli Carpén

ORCID: 0000-0002-7847-5706 · 3 papers in corpus
observational 2021
A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
Cancers ·doi:10.3390/cancers13081764

Epithelial ovarian cancer (EOC) generally responds well to oncological treatments, but the eventual development of a refractory disease is a major clinical problem. Presently, there are no prognostic blood-based biomarkers for the stratific…

diagnostic-accuracy 2020
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
The journal of applied laboratory medicine ·doi:10.1093/jalm/jfz012

BACKGROUND: The cancer antigen 125 (CA125) immunoassay (IA) does not distinguish epithelial ovarian cancer (EOC) from benign disease with the sensitivity needed in clinical practice. In recent studies, glycoforms of CA125 have shown potenti…

rct 2007
Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study
Human Reproduction ·doi:10.1093/humrep/dem235

BACKGROUND: Continuous administration of progesterone antagonists (PAs) results in endometrial suppression and amenorrhoea in several model systems. We compared the effects of intrauterine release of a highly specific PA, ZK230211, to those…